Session Information

Session Moderator

16:52 - 17:00  |  Presenter: Alessandra Curioni-Fontecedro

Session Moderator

16:52 - 17:00  |  Presenter: Kostas Syrigos

OA12.01 - Session Introduction

16:00 - 16:01  |  Presenter: Alessandra Curioni-Fontecedro

OA12.02 - Session Introduction

16:01 - 16:02  |  Presenter: Kostas Syrigos

OA12.03 - Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

16:02 - 16:12  |  Presenter: Jonathan Goldman

OA12.04 - Efficacy of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer after Chemo-Immunotherapy: A Phase 2 Trial.

16:12 - 16:22  |  Presenter: Dwight H Owen

OA12.05 - Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer

16:22 - 16:32  |  Presenter: Hossein Borghaei

OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

16:32 - 16:42  |  Presenter: Charles M Rudin

OA12.07 - Discussant

16:42 - 16:52  |  Presenter: Virginie Westeel

OA12.08 - Live Q&A

16:52 - 17:00

P2.01-01 - Association Between Clinical Outcomes and Local Treatment in Stage IV Non-small Cell Lung Cancer Patients With Single Extrathoracic Metastasis

P2.01-02 - Delivery of Concurrent Extracranial Stereotactic Body Radiotherapy With Osimertinib for Oligoprogressive EGFR Mutated Stage IV NSCLC

P2.02-01 - Value of Albumin-to-Globulin Ratio for Survival Prediction in Advanced Stage Non-Small Cell Lung Cancer Treated with Chemotherapy

P2.02-02 - A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy

P2.02-03 - A Phase II Study of Metformin with Pemetrexed/Carboplatin in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

P2.03-01 - Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT

P2.04-01 - Lung Cancer Patient Experience Survey from Twelfth Central and Eastern Europe Countries

P2.04-02 - Psychosocial Burdens in Cancer Caregivership, an Updated Overview

P2.04-03 - Perceptions and Knowledge of Electronic Smoking Devices among Patients with Solid Tumors and their Care-Givers

P2.04-05 - Is Opioid Use in the Management of Stage III Non-Small Cell Lung Cancer Patients Necessary?

P2.05-01 - The Effect of Treadmill Training on Cardiopulmonary, Health-related Quality of Life in Lung Cancer with Lobectomy

P2.06-01 - Skip Hilar Lymph Node Metastasis in Non-Small Cell Lung Cancer Has Similar Survival to N0 Disease: Need for a change in the pN sub-classification?

P2.07-01 - Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples

P2.07-02 - RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

P2.08-01 - Real-world barriers to clinical trial enrollment as reported by U.S. lung cancer patients and community cancer centers

P2.08-02 - Burning the Candle at Both Ends-Sleep Quality Before and After Chemotherapy in Lung Cancer Patients - A Systematic Review and Meta-Analysis

P2.08-03 - Patient Reported Lung Cancer Care Team Satisfaction and Treatment Dynamics, Based on the Online MyHealthTeams Survey

P2.08-04 - Patient Reported Impact of Lung Cancer Symptoms and Treatment on Mental Health and Quality of Life, Based on the Online MyHealthTeams Survey

P2.08-05 - Lung Cancer Patients’ Willingness to Attend a Screening Appointment or Lung Health Check: Insights from a Global Patient Experience Survey

P2.08-06 - Patient Involvement in Decision-Making around Their Treatment and Care: Findings from a Global Patient Experience Survey

P2.08-07 - The Campaign to End Lung Cancer Stigma: The ACS National Lung Cancer Roundtable Efforts to Confront and Extinguish Lung Cancer Stigma

P2.08-08 - Where Have All the Lung Cancer Support Groups Gone?

P2.08-09 - Adaptation of Empathic Communication Skills Training for Oncology Care Providers to Reduce Lung Cancer Stigma

P2.09-01 - MRI-based Radiomic Signature to Predict Pathologic High-grade Pattern in Lung Adenocarcinoma

P2.09-02 - Clinical Nodal (cN) Category Is Independently Prognostic for Overall Survival in Unresectable Advanced/Metastatic Lung Cancer

P2.09-03 - A Radiomics Approach Using Baseline CT Can Predict Response to 1st-Line Pembrolizumab in Advanced NSCLC with High PD-L1